AbbVie Inc.

It’s a big year for Regenxbio. The company has a potential commercial launch of its gene therapy program for MPS II (Hunter syndrome), a Biologics License Application for its Duchenne muscular dystrop

The six biosimilars to Johnson & Johnson ’s Stelara that have launched in the US have list prices 80% to 90% below the innovator’s wholesale acquisition cost, representing deeper discounts than t

The US Food and Drug Administration’s newly revised stand on testosterone labeling for cardiovascular risk is the visible tip of the metaphorical iceberg of years of effort that went into evaluating a

The six biosimilars to Johnson & Johnson ’s Stelara that have launched in the US have list prices 80% to 90% below the innovator’s wholesale acquisition cost, representing deeper discounts than t